Exact Sciences (EXAS, $125.72) to buy Thrive Earlier Detection for $2.5 billion

Molecular diagnostics company Exact Sciences  has agreed to buy cancer-detection company Thrive Earlier Detection for $2.5 billion in cash and stock.

Under the terms of the 65% stock-35% cash deal, Thrive Earlier Detection will receive $1.7 billion up front  . An additional $450 million will be payable to Thrive subject to milestones related to the development and commercialization of a blood-based, multi-cancer screening test.

Exact Sciences CEO Kevin Conroy said that the acquisition will allow Exact Sciences to add Thrive's early-stage cancer-screening test, CancerSEEK, into its blood-based screening platform.

Contributor

Sergey Savastiouk|Expert

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.